secwatch.observer — SEC 8-K summary
======================================

Issuer:     89bio, Inc. (—)
CIK:        0001785173
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001193125-24-135264
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

89bio reports Q1 net loss of $51.7M; initiates Phase 3 MASH trial
-----------------------------------------------------------------

- Net loss $51.7M vs $28.8M YoY; R&D expenses $47.4M (up from $22.3M) on trial ramp-up.
- Cash, equivalents & marketable securities $562.3M as of March 31, 2024.
- Initiated Phase 3 ENLIGHTEN-Fibrosis trial in MASH F2-F3; ENLIGHTEN-Cirrhosis expected Q2 2024.
- EMA granted PRIME status for pegozafermin in MASH; 48-week extension data at EASL June 8.
- ENTRUST Phase 3 in severe hypertriglyceridemia enrollment ongoing; topline data expected 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785173/000119312524135264/0001193125-24-135264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785173/000119312524135264/d793786d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-135264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer